A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) / G. Curigliano, S. Loibl, V. Müller, X. Pivot, A. Wardley, D. Cameron. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 27:Suppl. 6(2016 Oct 01). (Intervento presentato al 41. convegno ESMO Congress : October, 7th - 11th tenutosi a Copenhagen nel 2016) [10.1093/annonc/mdw365.91].
A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC)
G. Curigliano;
2016
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
AnnalsOncology_BreastCancer_2016.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
67.01 kB
Formato
Adobe PDF
|
67.01 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
